Protagonist Therapeutics: Buy the Royalty Tale, Backed by Two Near-Term Commercial Catalysts
Protagonist (PTGX) is trading like a pure clinical biotech despite meaningful de-risking: a partner-approved oral IL-23R pill (Icotyde) that just delivered a $50M milestone and an NDA for rusfertide in polycythemia vera moving toward potential approval. The shares have momentum, a $7.06B market cap and limited debt, creating a tradeable long with d…